默克-话题@MedSci

#默克#

100篇内容 | 3145人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1273969, encodeId=439612e39695a, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克创新佳-2022临床科研系列培训课重磅来袭~, objectType=article, longId=727253, objectId=dcd6e27253bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcd6e27253bd, replyNumber=0, likeNumber=61, createdTime=2022-05-20, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcd6e27253bd, moduleTitle=默克创新佳-2022临床科研系列培训课重磅来袭~, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dcd6e27253bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273968, encodeId=3f7712e396821, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=NICE推荐默克的Tepmetko (tepotinib) 用于治疗肺癌, objectType=article, longId=724443, objectId=0de7e2444352, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0de7e2444352, replyNumber=0, likeNumber=102, createdTime=2022-04-18, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0de7e2444352, moduleTitle=NICE推荐默克的Tepmetko (tepotinib) 用于治疗肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0de7e2444352)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273967, encodeId=e08212e39672e, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克与思路迪医药达成临床研究合作，共同探索创新“靶向+肿瘤免疫”联合疗法治疗转移性结直肠癌, objectType=article, longId=300740, objectId=1daa300e408c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1daa300e408c, replyNumber=0, likeNumber=103, createdTime=2022-03-16, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1daa300e408c, moduleTitle=默克与思路迪医药达成临床研究合作，共同探索创新“靶向+肿瘤免疫”联合疗法治疗转移性结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1daa300e408c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273966, encodeId=0da012e39666c, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=FDA咨询小组支持默克公司的口服COVID-19药物，但无法确定是否对Omicron变种有效, objectType=article, longId=221434, objectId=a66d221434cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a66d221434cd, replyNumber=0, likeNumber=93, createdTime=2021-12-04, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a66d221434cd, moduleTitle=FDA咨询小组支持默克公司的口服COVID-19药物，但无法确定是否对Omicron变种有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a66d221434cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273965, encodeId=048212e396538, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=2021年11月5日简报：本土疫情涉及到20个省份；英国成为批准默克新冠特效药的国家；国产乐复能也可能是新冠特效药之一, objectType=article, longId=219828, objectId=415c2198280a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=415c2198280a, replyNumber=0, likeNumber=77, createdTime=2021-11-06, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=415c2198280a, moduleTitle=2021年11月5日简报：本土疫情涉及到20个省份；英国成为批准默克新冠特效药的国家；国产乐复能也可能是新冠特效药之一, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=415c2198280a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273964, encodeId=f66b12e3964fa, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=FDA将召开咨询委员会会议，以讨论默克和Ridgeback的COVID-19口服疗法molnupiravir, objectType=article, longId=218760, objectId=f542218e60c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f542218e60c5, replyNumber=0, likeNumber=87, createdTime=2021-10-19, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f542218e60c5, moduleTitle=FDA将召开咨询委员会会议，以讨论默克和Ridgeback的COVID-19口服疗法molnupiravir, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f542218e60c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273963, encodeId=0af712e3963c0, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=英国药品和保健品监管局 (MHRA) 支持默克的MET抑制剂Tepmetko治疗非小细胞肺癌 (NSCLC) , objectType=article, longId=218571, objectId=7b4e2185e147, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b4e2185e147, replyNumber=0, likeNumber=89, createdTime=2021-10-16, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b4e2185e147, moduleTitle=英国药品和保健品监管局 (MHRA) 支持默克的MET抑制剂Tepmetko治疗非小细胞肺癌 (NSCLC) , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b4e2185e147)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273962, encodeId=3f7d12e396212, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=2021年10月6日简报：美国民众反智，奇葩新冠阴谋论流行，大批民众拒绝接种疫苗；欧洲药品管理局可能开始加速评估默克的新冠口服药；新西兰宣布放弃“彻底消除新冠”战略, objectType=article, longId=218164, objectId=c13c2181649c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c13c2181649c, replyNumber=0, likeNumber=80, createdTime=2021-10-07, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c13c2181649c, moduleTitle=2021年10月6日简报：美国民众反智，奇葩新冠阴谋论流行，大批民众拒绝接种疫苗；欧洲药品管理局可能开始加速评估默克的新冠口服药；新西兰宣布放弃“彻底消除新冠”战略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c13c2181649c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273961, encodeId=be5a12e396184, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克在ASCO21上呈报的肿瘤产品阵容数据突显癌症治疗的重大进展, objectType=article, longId=211773, objectId=81b4211e73f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81b4211e73f7, replyNumber=0, likeNumber=93, createdTime=2021-05-26, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81b4211e73f7, moduleTitle=默克在ASCO21上呈报的肿瘤产品阵容数据突显癌症治疗的重大进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81b4211e73f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273960, encodeId=244a12e396092, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克（Merck KGaA）的胆道癌疗法Bintrafusp Alfa，研究结果令人失望, objectType=article, longId=208490, objectId=f6302084901e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6302084901e, replyNumber=0, likeNumber=107, createdTime=2021-03-18, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6302084901e, moduleTitle=默克（Merck KGaA）的胆道癌疗法Bintrafusp Alfa，研究结果令人失望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6302084901e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273959, encodeId=e3da12e3959fa, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克与广药集团达成战略合作，推动大湾区业务创新发展, objectType=article, longId=207775, objectId=a45620e775a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a45620e775a9, replyNumber=0, likeNumber=95, createdTime=2021-03-02, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a45620e775a9, moduleTitle=默克与广药集团达成战略合作，推动大湾区业务创新发展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a45620e775a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273958, encodeId=be1312e3958b5, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克COVID-19新药MK-7110，显示出治疗希望！, objectType=article, longId=207663, objectId=2c3820e66379, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c3820e66379, replyNumber=0, likeNumber=80, createdTime=2021-02-28, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c3820e66379, moduleTitle=默克COVID-19新药MK-7110，显示出治疗希望！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c3820e66379)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273957, encodeId=eea412e39571f, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克尔：欧盟对任何新冠疫苗都持开放态度, objectType=article, longId=206752, objectId=4522206e5231, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4522206e5231, replyNumber=0, likeNumber=95, createdTime=2021-02-05, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4522206e5231, moduleTitle=默克尔：欧盟对任何新冠疫苗都持开放态度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4522206e5231)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273956, encodeId=3e6312e395692, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=Artiva Biotherapeutics宣布与默克公司达成**全球合作和许可协议，以开发候选CAR-NK细胞疗法, objectType=article, longId=206408, objectId=55db20640853, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55db20640853, replyNumber=0, likeNumber=88, createdTime=2021-01-31, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55db20640853, moduleTitle=Artiva Biotherapeutics宣布与默克公司达成**全球合作和许可协议，以开发候选CAR-NK细胞疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55db20640853)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273955, encodeId=50ec12e3955aa, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=欧盟将审查默克的肺癌靶向药物Tepotinib, objectType=article, longId=203863, objectId=2afa20386351, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2afa20386351, replyNumber=0, likeNumber=80, createdTime=2020-12-01, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2afa20386351, moduleTitle=欧盟将审查默克的肺癌靶向药物Tepotinib, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2afa20386351)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273954, encodeId=e4e812e39549a, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克PD-1单抗Keytruda：获得FDA批准乳腺癌适应症, objectType=article, longId=203465, objectId=f0b620346555, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0b620346555, replyNumber=0, likeNumber=92, createdTime=2020-11-17, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0b620346555, moduleTitle=默克PD-1单抗Keytruda：获得FDA批准乳腺癌适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0b620346555)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273953, encodeId=a4ac12e395350, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克27.5亿美元收购VelosBio，获得靶向ROR1的抗体-药物偶联物（ADC）, objectType=article, longId=203190, objectId=90cf20319062, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90cf20319062, replyNumber=0, likeNumber=83, createdTime=2020-11-11, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90cf20319062, moduleTitle=默克27.5亿美元收购VelosBio，获得靶向ROR1的抗体-药物偶联物（ADC）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90cf20319062)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273952, encodeId=c8af12e395250, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克（Merck）、IAVI和印度血清研究所合作开发COVID-19单克隆抗体, objectType=article, longId=202471, objectId=94642024e127, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94642024e127, replyNumber=0, likeNumber=103, createdTime=2020-10-26, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94642024e127, moduleTitle=默克（Merck）、IAVI和印度血清研究所合作开发COVID-19单克隆抗体, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94642024e127)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273951, encodeId=223012e3951a3, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=IDWeek 2020：默克公司将展示其广泛的抗感染药物研发管线, objectType=article, longId=202387, objectId=644e20238e88, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=644e20238e88, replyNumber=0, likeNumber=81, createdTime=2020-10-24, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=644e20238e88, moduleTitle=IDWeek 2020：默克公司将展示其广泛的抗感染药物研发管线, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=644e20238e88)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273950, encodeId=239512e3950b0, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=FDA批准默克的KEYTRUDA（派姆单抗），治疗复发或难治性经典霍奇金淋巴瘤（cHL）成年患者, objectType=article, longId=202168, objectId=22ff2021685a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22ff2021685a, replyNumber=0, likeNumber=81, createdTime=2020-10-17, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22ff2021685a, moduleTitle=FDA批准默克的KEYTRUDA（派姆单抗），治疗复发或难治性经典霍奇金淋巴瘤（cHL）成年患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22ff2021685a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

默克

2020-05-29

智者为医08 (审核中...)

前往app查看评论内容

#默克#

默克创新佳-2022临床科研系列培训课重磅来袭~

2022-05-20

智者为医08 (审核中...)

前往app查看评论内容

#默克#

NICE推荐默克的Tepmetko (tepotinib) 用于治疗肺癌

2022-04-18

智者为医08 (审核中...)

前往app查看评论内容

#默克#

默克与思路迪医药达成临床研究合作，共同探索创新“靶向+肿瘤免疫”联合疗法治疗转移性结直肠癌

2022-03-16

智者为医08 (审核中...)

前往app查看评论内容

#默克#

FDA咨询小组支持默克公司的口服COVID-19药物，但无法确定是否对Omicron变种有效

2021-12-04

智者为医08 (审核中...)

前往app查看评论内容

#默克#

2021年11月5日简报：本土疫情涉及到20个省份；英国成为批准默克新冠特效药的国家；国产乐复能也可能是新冠特效药之一

2021-11-06

智者为医08 (审核中...)

前往app查看评论内容

#默克#

FDA将召开咨询委员会会议，以讨论默克和Ridgeback的COVID-19口服疗法molnupiravir

2021-10-19

智者为医08 (审核中...)

前往app查看评论内容

#默克#

英国药品和保健品监管局 (MHRA) 支持默克的MET抑制剂Tepmetko治疗非小细胞肺癌 (NSCLC)

2021-10-16

智者为医08 (审核中...)

前往app查看评论内容

#默克#

2021年10月6日简报：美国民众反智，奇葩新冠阴谋论流行，大批民众拒绝接种疫苗；欧洲药品管理局可能开始加速评估默克的新冠口服药；新西兰宣布放弃“彻底消除新冠”战略

2021-10-07

智者为医08 (审核中...)

前往app查看评论内容

#默克#

默克在ASCO21上呈报的肿瘤产品阵容数据突显癌症治疗的重大进展

2021-05-26

智者为医08 (审核中...)

前往app查看评论内容

#默克#

默克（Merck KGaA）的胆道癌疗法Bintrafusp Alfa，研究结果令人失望

2021-03-18

makuansheng (审核中...)

前往app查看评论内容

#默克#

默克与广药集团达成战略合作，推动大湾区业务创新发展

2021-03-02

makuansheng (审核中...)

前往app查看评论内容

#默克#

默克COVID-19新药MK-7110，显示出治疗希望！

2021-02-28

makuansheng (审核中...)

前往app查看评论内容

#默克#

默克尔：欧盟对任何新冠疫苗都持开放态度

2021-02-05

makuansheng (审核中...)

前往app查看评论内容

#默克#

Artiva Biotherapeutics宣布与默克公司达成**全球合作和许可协议，以开发候选CAR-NK细胞疗法

2021-01-31

makuansheng (审核中...)

前往app查看评论内容

#默克#

欧盟将审查默克的肺癌靶向药物Tepotinib

2020-12-01

仁医06 (审核中...)

前往app查看评论内容

#默克#

默克PD-1单抗Keytruda：获得FDA批准乳腺癌适应症

2020-11-17

makuansheng (审核中...)

前往app查看评论内容

#默克#

默克27.5亿美元收购VelosBio，获得靶向ROR1的抗体-药物偶联物（ADC）

2020-11-11

makuansheng (审核中...)

前往app查看评论内容

#默克#

默克（Merck）、IAVI和印度血清研究所合作开发COVID-19单克隆抗体

2020-10-26

makuansheng (审核中...)

前往app查看评论内容

#默克#

IDWeek 2020：默克公司将展示其广泛的抗感染药物研发管线

2020-10-24

makuansheng (审核中...)

前往app查看评论内容

#默克#

FDA批准默克的KEYTRUDA（派姆单抗），治疗复发或难治性经典霍奇金淋巴瘤（cHL）成年患者

2020-10-17

科室
- - 订阅+
  - 更多科室
工具
服务